PRESS RELEASES

Date	Title
Jun 3, 2015	Ardelyx to Raise $77.8 Million in a Private Placement and Announces New Product Candidate for the Treatment of Hyperkalemia to Begin Clinical Development in Mid-2015
Jun 3, 2015	Ardelyx Regains Worldwide Development and Commercialization Rights for Its Late-Stage Development Candidate, Tenapanor, and Related Portfolio of NHE3 Compounds
May 19, 2015	Ardelyx Presents Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients at Digestive Disease Week 2015
May 12, 2015	Ardelyx Reports First Quarter 2015 Financial Results
May 5, 2015	Ardelyx Reports Results from Phase 2a Clinical Trial Evaluating Tenapanor in Chronic Kidney Disease Patients with Type 2 Diabetes Mellitus and Albuminuria
Apr 20, 2015	Ardelyx Appoints Dr. Annalisa Jenkins to Its Board of Directors
Mar 13, 2015	Ardelyx to Present at the 22nd Annual Future Leaders in the Biotech Industry Conference
Feb 25, 2015	Ardelyx Reports Fourth Quarter and Full Year 2014 Financial Results
Feb 18, 2015	Ardelyx to Report Fourth Quarter and Full Year 2014 Financial Results on February 25th, 2015
Feb 9, 2015	Ardelyx to Present at the 2015 Leerink Global Healthcare Conference

FAQs

Email Alerts

Connect

Bay Area
34175 Ardenwood Boulevard
Fremont, CA 94555

Greater Boston
400 Fifth Avenue, Suite 210
Waltham, MA 02451

Phone: 617.675.ARDX (2739)

Inquiries:
General: info@ardelyx.com
Media: media@ardelyx.com
Investor: investor@ardelyx.com
Business Development: partnering@ardelyx.com